Tranexamic acid: Difference between revisions
Ostermayer (talk | contribs) (Text replacement - " DVT " to " DVT") |
|||
(One intermediate revision by one other user not shown) | |||
Line 6: | Line 6: | ||
==Indication== | ==Indication== | ||
Severely bleeding trauma patient, systolic blood pressure of <90 and/or heart rate > 110 beats/min | Severely bleeding trauma patient, systolic blood pressure of <90 and/or heart rate > 110 beats/min, with expected requirement for massive transfusion. | ||
==Contraindication/Exclusion Criteria== | ==Contraindication/Exclusion Criteria== | ||
Line 27: | Line 27: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
*Thrombotic events | *Thrombotic events | ||
*Hypotension with rapid injection | *[[Hypotension]]with rapid injection | ||
*Nausea, vomiting, diarrhea | *Nausea, vomiting, diarrhea | ||
*Impaired color vision and other visual disturbances | *Impaired color vision and other visual disturbances |
Revision as of 18:07, 21 April 2019
Background
- Action: Antifibrinolytic agent
- Competitive inhibitor of plasminogen activation to plasmin
- Dosing Availability:
- Ampule of 1 Gm in 10 mL
Indication
Severely bleeding trauma patient, systolic blood pressure of <90 and/or heart rate > 110 beats/min, with expected requirement for massive transfusion.
Contraindication/Exclusion Criteria
- Greater than 3 hours from injury
- Known sensitivity to TXA
- Previous DVTor Pulmonary Embolism
Administration
Adult dose
Total of 2 Grams
- Initial bolus of 1 Gm over 10 minutes (Slow IV push). Draw up with filter needle.
- Maintenance: additional 1 Gm over next 8 hours (mix in 50 mL of NS). Call Pharmacy to mix and deliver the continuous infusion.[1]
Pediatric dose
Weight based
- Initial bolus of 20mg/kg IV Bolus over 10 minutes
- Maintenance: 10 mL/kg/hr over next 8 hours
No additional laboratory tests required.
Adverse Reactions
- Thrombotic events
- Hypotensionwith rapid injection
- Nausea, vomiting, diarrhea
- Impaired color vision and other visual disturbances
See Also
External Links
References
- ↑ CRASH-2 collaborators, Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, Morales C, Perel P, Prieto-Merino D, Woolley T. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011 Mar 26;377(9771):1096-101,